Skip to main content


Table 2 Previous treatments and trabectedin administration

From: Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group

Pt no. Prior systemic treat. before trab. Best RECIST response to systemic treatments Reason for discontinuing therapy Disease status just before starting trab. Numb of trab. cycles Dose decr. Reason for stopping trab.
1a A → SD → Stab. PD (L + M) 10 Y Stab.
Soraf n°1 → SD → Stab.
Soraf. n°2 → SD → Stab.
Soraf. n°3 → SD → Progr.
2 Soraf PD Progr. PD (M) 9 N Stab.
3 AI PD Progr. PD (L + M) 6 N Progr.
4 A PR Stab. PD (L + M) 12 Y Tox.
5 AI SD Stab. PD (M) 11 N Stab.
6 Ima → SD → Prog. PD (L + M) 12 N Stab.
AD → SD → Stab.
Cy → SD → Progr.
Soraf. → PD → Tox.
7 A → SD → Stab. PD (L + M) 2 N Progr.
Cy → PD → Progr.
Suni → SD → Progr.
Bev + Tmz → SD → Progr.
8 MAID SD Stab. PD (M) 4 N Tox.
9 AI SD Progr. PD (M) 3 N Progr.
10 AD SD Stab. PD (L + M) 6 N Stab.
11 PLK-Inh. PD Progr. PD (L + M) 11 N Progr.
  1. L local, M metastatic, trab. trabectedin, dose decr. dose decrease, A adriamycin, I ifosfamide, D dacarbazine, M Mesna, Cy cyclophosphamide, Soraf sorafenib, Ima imatinib, Suni sunitinib, Bev + Tmz bevacizumab + temozolomide, PLK-Inh Polo-Like Kinase inhibitor, SD stable disease, PD progressive disease, Y yes, N no, Stab disease stabilization, Progr disease progression, Tox toxicity
  2. aPatient 1 received sorafenib three times, in three successive lines of treatment